X4 Pharmaceuticals (XFOR) Exchange Rate Effect (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Exchange Rate Effect came in at $3000.0 in Q4 2025, up 101.23% YoY from $1490.8 in Q4 2024, and up 400.0% on a QoQ basis from -$1000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Exchange Rate Effect (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Exchange Rate Effect data on file, last reported at $3000.0 in Q4 2025.
- Quarterly Exchange Rate Effect rose 101.23% year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $213000.0 (up 236.54% YoY) and the FY2025 annual result came in at $213000.0, up 236.54% from the prior year.
- Exchange Rate Effect grew to $3000.0 in Q4 2025, from -$1000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $363000.0 in Q4 2022 to a low of -$244000.0 in Q4 2024.
- A 5-year average of -$13400.0 and a median of -$12000.0 in 2023 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2022 — Exchange Rate Effect plunged 605.0% — and 2025, when it soared 872.22%.
- Tracing XFOR's Exchange Rate Effect over 5 years: stood at -$116000.0 in 2021, then surged by 412.93% to $363000.0 in 2022, then slumped by 65.01% to $127000.0 in 2023, then sank by 292.13% to -$244000.0 in 2024, then soared by 101.23% to $3000.0 in 2025.
- The last three Exchange Rate Effect figures came in at $3000.0 (Q4 2025), -$1000.0 (Q3 2025), and $139000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | -244,000.00 |
| Dec 31, 2024 | -244,000.00 |
| Sep 30, 2024 | 165,000.00 |
| Sep 30, 2024 | 165,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | 127,000.00 |
| Dec 31, 2023 | 127,000.00 |
| Sep 30, 2023 | -72,000.00 |
| Sep 30, 2023 | -72,000.00 |